Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07098650

Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System

Haemdall: Using Medical Imaging to measure Brain Iron in Superficial Siderosis.

This study is looking at a new way of using MRI scans to potentially measure the amount of iron on the surface of the brain. Iron build up in the brain is linked to how superficial siderosis develops. The study will also aim to see if there is a connection between the amount of iron in the brain and common superficial siderosis symptoms. Clinical tests will be used to measure symptoms including tests to measure your hearing, walking & balance and participants' ability to remember, think and understand.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Superficial siderosis cohort:

  • Male or female adults of 18 years of age or older with a confirmed diagnosis of superficial siderosis
  • Participants who have the capacity and a level of English proficiency that allows him/her to communicate well with the Investigator, understand and comply with the requirements of the investigation, read all participant facing documentation, as well as read and sign the informed consent form.
  • Participants willing and able to give informed consent for participation in the investigation

Healthy cohort:

  • Male or female over 18 years of age without a diagnosis of a neurological disorder
  • Participants who have the capacity and a level of English proficiency that allows him/her to communicate well with the Investigator, understand and comply with the requirements of the investigation, read all participant facing documentation, as well as read and sign the informed consent form.
  • Participants willing and able to give informed consent for participation in the investigation

Exclusion criteria

  • The participant may not enter the investigation if they have any contraindication to magnetic resonance imaging (including pregnancy, extensive tattoos, pacemaker, shrapnel injury or metallic unfixed implanted devices, metallic fragments, severe claustrophobia and cochlear implants)
  • Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the investigation, or may influence the result of the investigation, or the participant's ability to participate in the investigation
  • Participants who do not demonstrate the capacity to understand the investigation information or provide informed consent

Treatment and study plan

Primary outcomes

  1. To evaluate the association and clinical relevance of with markers of neurodegeneration and clinical assessments

    Time frame: through study completion, an average of 1 year

    • Correlation between magnetic susceptibility assessed by QSM and brain cognitive function by MoCA.
    • Correlations between magnetic susceptibility assessed by QSM and: a) markers of neurodegeneration; and b) clinical assessment outcomes (auditory, balance, gait, cognitive)

Secondary outcomes

  1. Radiologist observational scoring and test-retest

    Time frame: through study completion, an average of 1 year

    • The agreement between radiologist scored observational level of iron accumulation via the Queens Square Superficial Siderosis (QUASARS) rating scale and quantitative MRI measure related to iron on the brain surface. The QUASARS rating is out of 36 points; with higher scores indicate a worse outcome
    • The repeatability coefficient within a single scanning session

Sponsors and collaborators

Lead sponsor

Perspectum

Industry

Registry information

Official study title

Haemdall: Developing a Quantitative MRI Biomarker of Classical (Infratentorial) Superficial Siderosis of the Central Nervous System

Acronym: Haemdall

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 1, 2025
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.